Exhibit 4.7
FORM 51-102F3
MATERIAL CHANGE REPORT
| Item 1: | Name and Address of Company |
Eupraxia Pharmaceuticals Inc. (the “Company”)
201-2067 Cadboro Bay Rd.
Victoria, British Columbia
Canada, V8R 5G4
| Item 2: | Date of Material Change |
May 18, 2023
A news release announcing the material change was issued on May 18, 2023 through Canada Newswire and a copy was subsequently filed on SEDAR.
| Item 4: | Summary of Material Change |
On May 18, 2023, the Company announced that it had appointed Mark Kowalski, MD, PhD, as the Company’s Chief Medical Officer (“CMO”).
| Item 5.1: | Full Description of Material Change |
On May 18, 2023, the Company announced that it had appointed Mark Kowalski, MD, PhD, as the Company’s CMO.
Dr. Kowalski has more than 20 years of experience in the pharmaceutical and biotech industry. He is a clinical leader, developing regulatory strategy and global clinical development plans for a variety of product types including small molecules, biologics (monoclonals, immunoconjugates, siRNAs) and vaccines, while working in a range of indications, including oncology, infectious diseases, urology, analgesia, allergy, rheumatology and metabolic disorders.
He brings to the Company experience with clinical study design, database design and authoring protocols for Phase 1 through 3 clinical trials, as well as medical monitoring and pharmacovigilance services for Phase 1 through 4 clinical trials, plus data analysis and writing of clinical study reports.
Dr. Kowalski held multiple senior roles, including Chief Medical Officer, at Sierra Oncology, a public company acquired by GSK plc in 2022 for US$1.9 billion.
Prior to that, he was the Chief Medical Officer and Senior Vice President at Arbutus Biopharma, a biotechnology company devoted to discovering and developing a cure for chronic Hepatitis B.
